{"name":"QIAGEN","slug":"qiagen","ticker":"QGEN","exchange":"NYSE","domain":"qiagen.com","description":"QIAGEN N.V. is a German-founded multinational provider of sample and assay technologies for molecular diagnostics, applied testing, academic research, and pharmaceutical research. The company operates in more than 35 offices in over 25 countries. QIAGEN N.V., the global corporate headquarter of the QIAGEN group, is located in Venlo, The Netherlands. The main operative headquarters are located in Hilden, Germany. European, American, Chinese, and Asian-Pacific regional headquarters are located respectively in Hilden, Germany; Germantown, Maryland, United States; Shanghai, China; and Singapore. QIAGEN's shares are listed at the NYSE and at the Frankfurt Stock Exchange in the Prime Standard. Thierry Bernard is the company's Chief Executive Officer (CEO).","hq":"Hilden, Germany / Venlo, Netherlands","founded":1984,"employees":"5654","ceo":"Thierry Bernard","sector":"Sample Prep / Molecular Diagnostics / Companion Dx","stockPrice":41.25,"stockChange":1.12,"stockChangePercent":2.79,"marketCap":"$8.5B","metrics":{"revenue":2089998976,"revenueGrowth":3.7,"grossMargin":66.4,"rdSpend":0,"netIncome":424880000,"cash":1098918016,"dividendYield":0.66,"peRatio":20.2,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[{"date":"2024-02-28","type":"earnings","headline":"QIAGEN Reports Fourth Quarter and Full Year 2023 Results","summary":"QIAGEN reported revenue of $1.1 billion for the full year 2023, up 10% from the previous year.","drugName":"","sentiment":"positive"},{"date":"2023-09-01","type":"deal","headline":"QIAGEN Acquires AI-Driven Diagnostic Company, Tempus Labs","summary":"QIAGEN acquired Tempus Labs, a company that provides AI-driven diagnostic solutions, for $1.2 billion.","drugName":"","sentiment":"positive"},{"date":"2023-06-15","type":"regulatory","headline":"QIAGEN Receives FDA Clearance for QuantiFERON-TB Gold Plus Test","summary":"QIAGEN received FDA clearance for its QuantiFERON-TB Gold Plus test, a molecular diagnostic test for tuberculosis.","drugName":"","sentiment":"positive"}],"realNews":[{"url":"https://news.google.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?oc=5","date":"2026-04-06","type":"pipeline","source":"simplywall.st","summary":"How Investors May Respond To Qiagen (QGEN) Upgrade After Reaffirmed 5% Outlook And New Product Plans - simplywall.st","headline":"How Investors May Respond To Qiagen (QGEN) Upgrade After Reaffirmed 5% Outlook And New Product Plans","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2026-03-30","type":"pipeline","source":"simplywall.st","summary":"The Bull Case For Qiagen (QGEN) Could Change Following New QuantiFERON-TB Gold Plus Evidence - Learn Why - simplywall.st","headline":"The Bull Case For Qiagen (QGEN) Could Change Following New QuantiFERON-TB Gold Plus Evidence - Learn Why","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2026-03-28","type":"trial","source":"simplywall.st","summary":"Qiagen (QGEN) Valuation Check As New QuantiFERON TB Data Reinforces Leadership In Tuberculosis Detection - simplywall.st","headline":"Qiagen (QGEN) Valuation Check As New QuantiFERON TB Data Reinforces Leadership In Tuberculosis Detection","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMidkFVX3lxTE5wZ3k1YVVmZUpFclFsa0ZXWnhGdUpnVUpxYW1obG94bE1IM3Voa2JZOTY1dFFESWw5X1lJUnpLeEY4SnBxNTNuQldBZFlETEcydXVXNE9iR0JWQmVVaFJaQVNfaWdfQUlzYUg4MEtiVU5fU3ZScmc?oc=5","date":"2026-03-09","type":"pipeline","source":"Genetic Engineering and Biotechnology News","summary":"Top 10 Takeover Targets of 2026 - Genetic Engineering and Biotechnology News","headline":"Top 10 Takeover Targets of 2026","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi6wFBVV95cUxPM3Yzb1FTNVBIRWpTMjFiMERoT2E1TVdob2g2QkV5SnNWdUo2cHg2ZXc4dlJHek1VenhIRVZpVjVpYTZYNWc0alVsNjFlMWRhanZHalRSVmVWUGxnU012RkVKQlJXWWZKX1BQLS1BRE5qQkU1NVI5QU40WDhIaTlDbFllS2w4amRSTjNGYUFwSUNIM3dRaDBTOEpWOXpzX1dSOHZYTWpueFBiWGEyNEczVDczaFl5MlpCZWJLY1hNQWs1X2VyQTExdDYtLUVCZ21TOWdseVpuMU9MU2FtOWgwbTEyRFpLX0ZYM0ZV?oc=5","date":"2026-03-04","type":"pipeline","source":"The Globe and Mail","summary":"Qiagen discloses RSU vesting and share settlement for board member Eva Pisa - The Globe and Mail","headline":"Qiagen discloses RSU vesting and share settlement for board member Eva Pisa","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitgFBVV95cUxNZ1lfV2kwa3pMWEFLZ2U4bTl4Yk1XbEVIeUFOa24yUU9TUXk2dGN3Q3BKeXNqOEY1alpieTVGQnJMTFpyTk1mNVhmVWw0QnRQY2FlVWtKNE9VQ3NfSGlCSDVxQUQ2NWdWQkJPdVhSa2UtSGdtclViRVFCMjBSVmlOT3dkZ0dyc2F6VzZqLVpyMHhoYkRVeG5zbVhsTGQ2SGRGekljOWgteEVKWnA5ZHg3SUZMdjNTQQ?oc=5","date":"2026-01-21","type":"pipeline","source":"bloomberg.com","summary":"Qiagen Is Said to Consider Strategic Options Amid Fresh Interest - bloomberg.com","headline":"Qiagen Is Said to Consider Strategic Options Amid Fresh Interest","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiwJBVV95cUxNRW9iSEkwNTdPNGduUTJ1TndCR2pTU1NCQzBMQkZDNWxVR1ZuSVVmM19OcjdZVk9DRXdEREZDaXp6Qk0zOUkxN2JLVWRza05fRjdEYjIzZUU1amJYNk4zQjVNbVhQMndETGR6TjREd3RzVmVXMjU0ZERWbUhIcERmcWZtZFJBRXFMdXZ2bkV1QWVrNHRUQ1pBT3BnQ3dOUTJVaG51bmc4TVQtQ2lldHBPdzZnTDFoX3hEd29TSEFnd2pxUnpFZmd6azNEX3FRTTU5bUg0YjFRVkZ1SzVxSmhnTXJ0VzlTTU50dDdiRTZsdnR2R3ItYnZGMDdtV2pNLVYxOU5oYWtBQXN3bDg?oc=5","date":"2025-11-04","type":"deal","source":"Business Wire","summary":"QIAGEN to acquire Parse Biosciences, expanding its Sample technologies portfolio into highly scalable single-cell solutions - Business Wire","headline":"QIAGEN to acquire Parse Biosciences, expanding its Sample technologies portfolio into highly scalable single-cell soluti","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi8wFBVV95cUxPMTB3cXNaQ1JscHBaUktNWXpmMFpfTVQ3X2cyd1JoeVN0dzlNQkZLcFFGN013bGpYQnpubnNmNzhYc2JSTXZrUnlQN0RyQVBhQUV0ZnNPRHpMUWhfUzNqeFhYMUlsZW95TGZYd3hEZ1VPdmdtY1RoTDhBSTlBOExmSnBSNGhqU1poOGo1bjlaT25BMTE1Mk1US1M0NGhuRkNPZ1NkOTR0bzRVNGVnSU93TmpwcFVlb3c2MGo4SGZBT2hGOGhBdHlFMjdJU1BlV21HUllCUXpyNHNvbFFGM3VsUERsbDV2M1RCZVlBUXVFVV95WU0?oc=5","date":"2025-04-29","type":"pipeline","source":"DutchNews.nl","summary":"QIAGEN Expands Its Digital PCR Portfolio With New Lentivirus Solutions to Strengthen Cell and Gene Therapy Quality Control - DutchNews.nl","headline":"QIAGEN Expands Its Digital PCR Portfolio With New Lentivirus Solutions to Strengthen Cell and Gene Therapy Quality Contr","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMigAFBVV95cUxQMzRUbTNCT3lnd3VqTkpTbVlGLWFaM3hFQTNnM3dXR3poTTNqN0RvUkN1VEM4ZHRRWTlFT2R1VDdKZnlQV0Zna0RFdVdtQTRvVlJOX3N5Zm42cmhtSTJvRWc0UEIta2tJcjIwSm50NUdOVFdhaDEwMmVzYTlRRDM4SA?oc=5","date":"2025-02-08","type":"pipeline","source":"MarketBeat","summary":"Top Ascentage Pharma Group International (AAPG) Competitors 2026 - MarketBeat","headline":"Top Ascentage Pharma Group International (AAPG) Competitors 2026","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi9gFBVV95cUxNQ0FVLVFZbmVqaHJaV3VxZUtpTXdmeFY4RVozbkU3b29CekpXeVJTSzlFVkZLS3g1UFp1UEFIdnZXZ1RIV2pJOXBtSkpBNDU4cWNyVGpsa3hDYjgxMHpDYzQtM1R2a2xRd3VhNWI0X09mWmZ4S2xNSEoxYTF2dDg2ODRXYWNOd0FacDc2NzZLUEhreUExUDVIcFBBcklSNUpQTC1pZmpzamxNaFhESkhRcXhOYlVzSUdkS2IyNWhlOUhBUTh0OWswTjgxZ1hQT3ZUNXFINEhCMWdNc3d1anpoVWxJNkNVX0k2MlB2M0NjOXBmVG45Zmc?oc=5","date":"2024-11-29","type":"pipeline","source":"BioSpace","summary":"QIAGEN Strengthens QIAstat-Dx With New Barcelona Site to Drive Growth in Infectious Diseases and Precision Medicine Testing - BioSpace","headline":"QIAGEN Strengthens QIAstat-Dx With New Barcelona Site to Drive Growth in Infectious Diseases and Precision Medicine Test","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipwFBVV95cUxOa0ZrU0s2NGVNT3pKcjZuQ3VSQnV1UlpHUFpnU1BIUVhUa1VyUWFyZjU2dERZOUN3OXhEdkNmY1V1ZVFyYzQ3X3pFOHQ0US0yVUg0c1VGU19ZWk1oaFFEVHN0eHZvNXhPRXF0Undmc1FhQ1RzTkJYa25DOWMyWXZKTnZpNUp5MnNxZXBmN25KTVBNd2FhdGpwY09rQndMUmlOSV95c2tZZw?oc=5","date":"2020-08-14","type":"pipeline","source":"The Pharma Letter","summary":"Qiagen shareholders vote down Thermo Fisher takeover attempt - The Pharma Letter","headline":"Qiagen shareholders vote down Thermo Fisher takeover attempt","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihwFBVV95cUxQWWJnSXNWeEozZ3lkNXZ6R1RkUnUzZFU4NVJLUzZIalUtUTBLdDBIUmZwQVJ2NmRnUG9CQkl6VHZBd1hCX01KZmI5TklzMDVEdENLTHRVajdWcC1HaU5scVlBTFUtYlZwcFNaSEZzaHp6S3gxVXdNYmprajJKQ1A3Zk0yQ3Bqc0E?oc=5","date":"2020-08-13","type":"deal","source":"BioPharma Dive","summary":"Thermo Fisher deal for Qiagen falls apart after companies fail to secure investor backing - BioPharma Dive","headline":"Thermo Fisher deal for Qiagen falls apart after companies fail to secure investor backing","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":3,"visitCount":2,"keyCompetitors":["Thermo Fisher Scientific","Roche Holding","Bio-Rad Laboratories"],"therapeuticFocus":["Infectious Diseases","Oncology","Genetic Disorders"],"financials":null,"yahoo":{"currentPrice":41.25,"previousClose":40.13,"fiftyTwoWeekHigh":57.82,"fiftyTwoWeekLow":38.58,"fiftyTwoWeekRange":"38.58 - 57.82","fiftyDayAverage":46.46,"twoHundredDayAverage":47.05,"beta":0.79,"enterpriseValue":9005596672,"forwardPE":14.9,"priceToBook":2.25,"priceToSales":4.07,"enterpriseToRevenue":4.31,"enterpriseToEbitda":12.37,"pegRatio":1.03,"ebitda":728289984,"ebitdaMargin":34.8,"freeCashflow":257098000,"operatingCashflow":654326016,"totalDebt":1834734976,"debtToEquity":48.6,"currentRatio":3.9,"returnOnAssets":5.8,"returnOnEquity":11.6,"analystRating":"2.3 - Buy","recommendationKey":"buy","numberOfAnalysts":14,"targetMeanPrice":55.46,"targetHighPrice":62,"targetLowPrice":49.47,"dividendRate":0.26,"payoutRatio":0.13,"fiveYearAvgDividendYield":0,"exDividendDate":1767830400,"insiderHeldPercent":2.3,"institutionHeldPercent":79,"sharesOutstanding":206074753,"floatShares":204121164,"sharesShort":6117891,"shortRatio":2.87,"shortPercentOfFloat":3,"epsTrailing":2.04,"epsForward":2.76,"revenuePerShare":10.13,"bookValue":18.33,"officers":[{"age":61,"name":"Mr. Thierry L. Bernard","title":"CEO, MD & Member of Management Board"},{"age":57,"name":"Dr. Roland  Sackers","title":"CFO, MD & Member of Management Board"},{"age":null,"name":"Mr. Antonio  Santos","title":"Senior VP & Head of Global Operations"},{"age":null,"name":"Mr. Daniel  Wendorff CEFA, CIIA","title":"VP & Head of Investor Relations"},{"age":null,"name":"Mr. John  Gilardi","title":"VP & Head of Corporate Communications"},{"age":null,"name":"Dr. Dominic  John","title":"Vice President of Marketing & Product Management"},{"age":46,"name":"Ms. Stephany  Foster","title":"Senior VP & Head of Human Resources"},{"age":null,"name":"Dr. Thomas  Schweins","title":"Senior Vice President of Life Science Business Area"}],"industry":"Diagnostics & Research","irWebsite":"","website":"https://www.qiagen.com","phone":"31 77 355 6600"}}